How much funding has Novamab raised?

Novamab has raised $84.8M in total funding, most recently a Series B round.

Who are Novamab's investors?

Novamab's investors include Qiming VP, Huangpu Biomedical Fund, Jiuyu Investment.

Where is Novamab headquartered?

Novamab is headquartered in Shanghai, China.

What industry is Novamab in?

Novamab operates in Biotech, Healthcare.

Novamab

Shanghai, China · Founded 2017 · $84.8M raised

Biotech

Healthcare

Headquarters: Shanghai
Employees: 51–200
Founded: 2017
Business Model: B2B

Website: en.novamab.com
Total Funding: $84.8M
Last Round: $31.6M Series BApr 2024
Rounds: 3

About

NovaMab (Shanghai Novamab Biopharmaceuticals Co., Ltd.) is a clinical-stage biotech company founded in 2017 and headquartered in the Shanghai International Medical Park, Pudong New Area, Shanghai, China. The company is dedicated to creating life-changing therapies through innovative VHH (single domain antibody) technology, with a highly differentiated pipeline targeting high-potential markets including asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). NovaMab's most advanced program, an inhaled IL-4R VHH antibody (LQ036), has progressed to Phase IIb clinical trials, while its inhaled TSLP VHH (LQ043H) is entering Phase IB studies. The company operates a 500L GMP workshop for VHH antibody production using Pichia pastoris, holds over 100 patents, and has been recognized among China's top 50 innovative biopharmaceutical enterprises.

Summary

Novamab is a Biotech company based in Shanghai, China, founded in 2017. It has raised $84.8M in total across 3 rounds, most recently a $31.6M Series B round in Apr 2024. Investors include Qiming VP, Huangpu Biomedical Fund and Jiuyu Investment.